Figure 1From: Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial Mean number of new T2 lesions (nT2L) and gadolinium enhancing lesions (Gd+L) per patient at baseline and at month 3, 6, 9 and 12 of study (statistical analysis was performed with non parametric tests and reported in Results and Table 2 ). Back to article page